Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 207
interventional 150
Observational 53
Registry 4

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 69
Drug|placebo 42
Procedure 13
Device 9
Other 6
Behavioral 2
Device|Other 2
Device|placebo 2
Diagnostic Test 1
Dietary Supplement 1
Drug|Other|Procedure 1
Drug|Procedure 1
Other|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 45
Japan 16
NA 13
Korea, Republic of 8
United Kingdom 7
Belgium 5
United States|Canada 4
China 3
Austria 2
Colombia 2
France 2
Germany 2
Russian Federation 2
Taiwan 2
Argentina|Australia|Austria|Belgium|Brazil|Canada|France|Germany|Hong Kong|India|Italy|Korea, Republic of|Malaysia|Mexico|Poland|Portugal|Singapore|South Africa|Spain|Switzerland|Taiwan|United Kingdom 1
Australia 1
Austria|Belgium|Denmark|Finland|France|Germany|Iceland|Italy|Netherlands|Norway|Sweden|United Kingdom 1
Austria|Belgium|France|Germany 1
Austria|Germany|Hungary|Poland 1
Belgium|France|Germany|Switzerland 1
Belgium|France|Sweden 1
Brazil|Germany|Poland|South Africa 1
Chile 1
Chile|Argentina|Colombia|Venezuela 1
China|Korea, Republic of 1
Denmark 1
Germany|Australia|Belgium|France|Hungary|Netherlands|Norway|Romania 1
Germany|Hungary|United States|Australia|Bulgaria|Canada|Czech Republic|India|Latvia|Lithuania|New Zealand|Peru|Poland|Slovakia|South Africa 1
Greece 1
Hong Kong|Korea, Republic of|Taiwan 1
Italy 1
Malaysia 1
Mexico 1
Netherlands 1
Norway 1
Poland 1
Singapore 1
Spain 1
Thailand 1
United States|Argentina|Australia|Bulgaria|Canada|Chile|Croatia|Estonia|France|Germany|Hungary|India|Latvia 1
United States|Argentina|Australia|Bulgaria|Canada|Chile|Croatia|Estonia|France|Germany|Hungary|India|Latvia|Lithuania 1
United States|Australia|Belgium|Canada|France|Germany|Italy|Netherlands|Poland|South Africa|Switzerland 1
United States|Australia|Bulgaria|Canada|Colombia|Czech Republic|Germany|India|Latvia|Lithuania|New Zealand|Peru|Poland|Russian Federation|Slovakia|South Africa 1
United States|Australia|Canada|Czech Republic|Estonia|Latvia|Lithuania|Slovakia 1
United States|Austria|Germany|India|Italy 1
United States|Belgium|Brazil|Hungary|Italy|Mexico|Poland|Portugal 1
United States|Belgium|Brazil|Poland|United Kingdom 1
United States|Czech Republic|Germany|Latvia|Poland|Romania 1
United States|France|Germany|Netherlands|Switzerland 1
United States|Germany|Poland|United Kingdom 1
United States|Poland 1

Sites per Study

Site_count Study_Count
1 78
2 3
3 1
4 5
5 2
6 2
7 2
10 3
11 1
12 1
13 1
14 1
15 1
17 2
19 1
20 1
25 2
26 1
30 1
35 2
38 2
39 1
40 1
41 1
43 2
44 1
45 3
51 1
52 2
54 1
59 1
61 1
62 1
63 1
64 1
65 1
71 1
79 1
83 1
85 1
88 2
95 1
96 1
98 2
99 1
100 1
102 1
103 1
140 1
144 1
153 1
186 1

Phase

Phase Study_Count
Phase 3 50
N/A 38
Phase 4 26
Phase 2 16
Phase 1 15
Phase 2/Phase 3 4
Phase 1/Phase 2 1

Number of Arms

Number_of_Arms Count_of_Studies
1 27
2 67
3 20
4 8
5 4
NA 24

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 10.00000 15.00000 12 24.0000 24.00 18.00 2.0000
1st Qu. 20.75000 24.00000 12 98.5000 44.25 127.50 62.0000
Median 52.00000 34.00000 12 154.0000 194.00 315.00 117.0000
Mean 98.66667 49.46667 12 210.0667 223.00 519.38 246.5385
3rd Qu. 128.25000 49.00000 12 290.0000 372.75 660.00 299.0000
Max. 500.00000 250.00000 12 503.0000 480.00 2054.00 1392.0000

Trial Group Type

group_type Group_Count
Experimental 157
Active Comparator 58
Placebo Comparator 36
NA 24
Other 16
No Intervention 3
Sham Comparator 3

Intervention Model

intervention_model Study_Count
Parallel Assignment 96
Single Group Assignment 32
Crossover Assignment 19
NA 3

Primary Purpose

primary_purpose Study_Count
Treatment 124
Basic Science 8
Diagnostic 6
NA 5
Other 3
Prevention 2
Device Feasibility 1
Health Services Research 1

Observational Studies

Studies by Country

Country Study_Count
United States 12
Japan 6
Italy 5
NA 5
China 4
Korea, Republic of 3
Taiwan 3
Brazil 2
Bulgaria 2
Germany 2
Greece 2
Bosnia and Herzegovina 1
Croatia 1
Hong Kong 1
Malaysia 1
Saudi Arabia 1
Switzerland 1
United Kingdom 1

Sites per Study

Site_count Study_Count
1 37
2 3
4 1
7 1
12 1
19 1
23 1
25 1
32 1
46 1
47 2
54 1
259 1
447 1

Enrollment Metrics

Measure Observational
Min 8.000
1st Qu 72.000
Median 374.000
Mean 2396.415
3rd Qu 2000.000
Max 50000.000

Observation Model

observational_model Study_Count
Cohort 26
Case-Only 10
Case-Control 5
NA 5
Case Control 4
Other 3

Time Perspective

time_perspective Study_Count
Prospective 36
Cross-Sectional 10
Retrospective 7

Registries

Studies by Country

Country Study_Count
Azerbaijan 1
Denmark 1
Egypt 1
Korea, Republic of 1

Sites per Study

Site_count Study_Count
1 4

Enrollment Metrics

Measure Registries
Min 80
1st Qu 95
Median 550
Mean 25295
3rd Qu 25750
Max 100000

Registry Model

observational_model Study_Count
Cohort 2
Case Control 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 4

Follow-up

target_duration Study_Count
12 Months 1
2 Years 1
3 Months 1
6 Weeks 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03553563 A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer https://ClinicalTrials.gov/show/NCT03553563 Recruiting AstraZeneca 2023-01-04
NCT03259191 Anti-reflux Mucosectomy (ARMS) is a Useful Therapy for Refractory Gastroesophageal Reflux Disease (RGERD) https://ClinicalTrials.gov/show/NCT03259191 Recruiting Zhongda Hospital 2017-11-20
NCT03184324 Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study) https://ClinicalTrials.gov/show/NCT03184324 Completed Daewoong Pharmaceutical Co. LTD. 2018-04-18
NCT03130543 A Trial of Thickened Feeds to Treat Gastroesophageal Reflux in Children Admitted After Choking Spell https://ClinicalTrials.gov/show/NCT03130543 Recruiting Boston Children’s Hospital 2022-03-06
NCT03116841 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation https://ClinicalTrials.gov/show/NCT03116841 Completed Takeda 2017-12-20
NCT02907632 Methoclopramide for Gastroesophageal Reflux in Premature Infants https://ClinicalTrials.gov/show/NCT02907632 Recruiting Kangaroo Foundation 2019-01-31
NCT02890979 Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT02890979 Active, not recruiting OHSU Knight Cancer Institute 2020-12-31
NCT02860624 Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients https://ClinicalTrials.gov/show/NCT02860624 Completed Livzon Pharmaceutical Group Inc. 2013-04-30
NCT02755753 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis https://ClinicalTrials.gov/show/NCT02755753 Completed Severance Hospital 2016-01-31
NCT02706938 Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT02706938 Completed Universidad Nacional de Colombia 2017-11-15
NCT02637557 A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT02637557 Completed Ironwood Pharmaceuticals, Inc. 2017-04-26
NCT02620241 Influence of Intrapulmonary Percussive Ventilation (IPV) on Gastro-oesophageal Reflux (GOR). https://ClinicalTrials.gov/show/NCT02620241 Completed Vrije Universiteit Brussel 2017-10-31
NCT03388047 Feasibility of Multi-Spectral Endoscopic Imaging for Detection of Early Neoplasia in Barrett’s Oesophagus https://ClinicalTrials.gov/show/NCT03388047 Recruiting University of Cambridge 2020-12-31
NCT02513784 Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome https://ClinicalTrials.gov/show/NCT02513784 Completed Columbia University 2017-12-31
NCT02463643 To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis https://ClinicalTrials.gov/show/NCT02463643 Completed Zeria Pharmaceutical 2016-10-31
NCT02457429 A Validation Study of the Dx-pH Probe in Children for the Detection of Extra-oesophageal Reflux https://ClinicalTrials.gov/show/NCT02457429 Completed Manchester University NHS Foundation Trust 2017-04-28
NCT02429830 A Study of Reflux Management With the LINX® System for Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy https://ClinicalTrials.gov/show/NCT02429830 Active, not recruiting Torax Medical Incorporated 2021-12-31
NCT02351960 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT02351960 Completed Takeda 2016-06-22
NCT02153398 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases https://ClinicalTrials.gov/show/NCT02153398 Completed AstraZeneca 2016-04-30
NCT02135107 A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients https://ClinicalTrials.gov/show/NCT02135107 Completed Eisai Inc. 2016-05-31
NCT02030925 Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors https://ClinicalTrials.gov/show/NCT02030925 Completed Ironwood Pharmaceuticals, Inc. 2014-12-31
NCT03346174 Influence of Airway Clearance Techniques on GOR in Infants https://ClinicalTrials.gov/show/NCT03346174 Recruiting Vrije Universiteit Brussel 2021-01-01
NCT01964131 BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects https://ClinicalTrials.gov/show/NCT01964131 Completed AstraZeneca 2013-12-31
NCT01946971 Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER) https://ClinicalTrials.gov/show/NCT01946971 Completed Seoul National University Hospital 2014-07-31
NCT01888549 Efficacy of Proton Pump Inhibitor for Chronic Cough Caused by Gastroesophageal Reflux; Double-blind, Placebo-controlled, Randomized Clinical Trial https://ClinicalTrials.gov/show/NCT01888549 Completed Yonsei University 2016-02-29
NCT01882088 Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD https://ClinicalTrials.gov/show/NCT01882088 Completed Russian Academy of Medical Sciences 2016-09-30
NCT01878526 Gastroesophageal Reflux Treatment in Scleroderma https://ClinicalTrials.gov/show/NCT01878526 Completed Khon Kaen University 2015-08-31
NCT01860482 The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD https://ClinicalTrials.gov/show/NCT01860482 Completed Chong Kun Dang Pharmaceutical 2015-05-31
NCT01818570 A Study of Local Effect and Safety of a Single PPC-5650 Dose on Reflux Pain During Pain Stimulation in the Esophagus https://ClinicalTrials.gov/show/NCT01818570 Completed Aalborg University Hospital 2014-01-31
NCT01733810 The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis https://ClinicalTrials.gov/show/NCT01733810 Completed Dallas VA Medical Center 2015-07-31
NCT01669811 Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus) https://ClinicalTrials.gov/show/NCT01669811 Completed AstraZeneca 2014-05-31
NCT01642602 Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents https://ClinicalTrials.gov/show/NCT01642602 Completed Takeda 2014-01-31
NCT01599858 Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers https://ClinicalTrials.gov/show/NCT01599858 Completed Trio Medicines Ltd. 1996-10-31
NCT01597674 Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers https://ClinicalTrials.gov/show/NCT01597674 Completed Trio Medicines Ltd. 1997-06-30
NCT01578642 Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT01578642 Completed EndoStim Inc. 2013-05-31
NCT01570842 Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury https://ClinicalTrials.gov/show/NCT01570842 Completed Mayo Clinic 2012-11-30
NCT01538849 Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis https://ClinicalTrials.gov/show/NCT01538849 Completed Yuhan Corporation 2013-11-30
NCT01538797 Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States https://ClinicalTrials.gov/show/NCT01538797 Completed Trio Medicines Ltd. 1996-08-31
NCT01538784 Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men https://ClinicalTrials.gov/show/NCT01538784 Completed Trio Medicines Ltd. 1996-06-30
NCT01493089 Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT01493089 Completed Norgine 2011-10-31
NCT01474369 Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT01474369 Completed Takeda 2013-02-28
NCT01472939 Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT01472939 Completed Shire 2013-05-31
NCT01400945 Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT01400945 Completed Ahn-Gook Pharmaceuticals Co.,Ltd 2011-08-31
NCT01397084 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole https://ClinicalTrials.gov/show/NCT01397084 Completed AstraZeneca 2012-01-31
NCT01381991 The Efficacy of i-Scan for Detecting Reflux Esophagitis https://ClinicalTrials.gov/show/NCT01381991 Completed Konkuk University Hospital 2010-11-30
NCT01324986 A Study on the Effectiveness of Laparoscopic Fundoplication on Extraesophageal Manifestations of Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT01324986 Completed General Public Hospital Zell am See NA
NCT01324791 Laparoscopic Antireflux Surgery Versus Endoscopic Full-thickness Gastroplication for Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT01324791 Completed General Public Hospital Zell am See NA
NCT04255693 Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence https://ClinicalTrials.gov/show/NCT04255693 Recruiting Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology 2023-12-31
NCT04202692 Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment https://ClinicalTrials.gov/show/NCT04202692 Recruiting SOFAR S.p.A. 2020-12-31
NCT04036942 Antireflux Ablation Therapy (ARAT) Vs Antireflux Mucosectomy (ARMS) In The Management Of Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT04036942 Recruiting Coordinación de Investigación en Salud, Mexico 2019-11-01
NCT03883074 Effect of a Combination of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate on Subjects With GastroEsophageal Reflux Disease https://ClinicalTrials.gov/show/NCT03883074 Recruiting SOFAR S.p.A. 2020-10-31
NCT03788109 Relationship Between Gastric Accommodation, TLESRs and Reflux in HV and in GERD With or Without Overlapping Dyspepsia https://ClinicalTrials.gov/show/NCT03788109 Completed Universitaire Ziekenhuizen Leuven 2018-06-15
NCT03634449 Risks of Gastroesophageal Reflux in the Endotracheal Intubation or the I-gel https://ClinicalTrials.gov/show/NCT03634449 Recruiting National Taiwan University Hospital 2019-10-13
NCT03619811 Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT03619811 Recruiting University of California, San Diego 2020-07-31
NCT03561883 Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors https://ClinicalTrials.gov/show/NCT03561883 Recruiting Ironwood Pharmaceuticals, Inc. 2021-06-30
NCT03561233 Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03561233 Completed Khon Kaen University 2018-05-31
NCT03516188 Efficacy of Gaviscon-Advance® in Suppressing Post-supper Acid-pocket and Night-time Acid-reflux in Obese Participants https://ClinicalTrials.gov/show/NCT03516188 Completed Universiti Sains Malaysia 2017-06-30
NCT03497494 the Related Factors of Bariatric Surgery on Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT03497494 Active, not recruiting First Affiliated Hospital of Jinan University 2019-12-30
NCT03467438 Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT03467438 Recruiting IRCCS Policlinico S. Matteo 2020-04-01
NCT03425097 Fexofenadine Use in Gastroesophageal Reflux Symptoms https://ClinicalTrials.gov/show/NCT03425097 Recruiting Stanford University 2020-03-31
NCT01260935 Comparison of Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures https://ClinicalTrials.gov/show/NCT01260935 Completed Swedish Medical Center 2010-11-30
NCT01161602 A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT01161602 Completed Edusa Pharmaceuticals, Inc. NA
NCT01118585 Transoral Incisionless Fundoplication (TIF) Registry Study for Treatment of Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT01118585 Completed EndoGastric Solutions 2015-06-30
NCT01110811 Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT01110811 Completed EndoGastric Solutions 2015-09-30
NCT01045096 Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT01045096 Completed Takeda 2011-02-28
NCT01043185 A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience https://ClinicalTrials.gov/show/NCT01043185 Completed AstraZeneca 2010-05-31
NCT01039558 The Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT01039558 Completed Seoul National University Hospital 2011-03-31
NCT01008696 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis https://ClinicalTrials.gov/show/NCT01008696 Completed Janssen Korea, Ltd., Korea 2008-08-31
NCT00998244 Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00998244 Completed University of North Carolina, Chapel Hill 2011-12-31
NCT00978016 A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00978016 Completed Indivior Inc. 2010-12-31
NCT00926276 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia https://ClinicalTrials.gov/show/NCT00926276 Completed The University of Texas Health Science Center, Houston 2013-05-31
NCT00911534 Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD) https://ClinicalTrials.gov/show/NCT00911534 Completed Eisai Inc. 2009-07-31
NCT00872755 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00872755 Completed G. Hatzikosta General Hospital 2008-04-30
NCT00868296 Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00868296 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2008-03-31
NCT00855361 A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00855361 Completed Janssen Research & Development, LLC 2011-12-31
NCT00847808 Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy https://ClinicalTrials.gov/show/NCT00847808 Completed Takeda 2010-04-30
NCT00847210 Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00847210 Completed Takeda 2009-09-30
NCT00839306 Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00839306 Completed Eisai Inc. 2009-08-31
NCT00838526 Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00838526 Completed Eisai Inc. 2009-07-31
NCT00810485 ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD) https://ClinicalTrials.gov/show/NCT00810485 Completed Addex Pharma S.A. 2009-12-31
NCT03561090 A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors https://ClinicalTrials.gov/show/NCT03561090 Recruiting Ironwood Pharmaceuticals, Inc. 2021-06-30
NCT03299985 Diaphragmatic Myofascial Release in Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT03299985 Completed Cardenal Herrera University 2018-03-15
NCT02954848 Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD) https://ClinicalTrials.gov/show/NCT02954848 Completed Takeda 2018-02-25
NCT00787891 A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients https://ClinicalTrials.gov/show/NCT00787891 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2011-01-31
NCT00786695 Study Using Esomeprazole as a Diagnostic Test for GERD in Patients With NCCP https://ClinicalTrials.gov/show/NCT00786695 Completed National University Hospital, Singapore 2009-12-31
NCT00770913 Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis https://ClinicalTrials.gov/show/NCT00770913 Completed Eisai Inc. 2009-11-30
NCT02124863 Influence of IPV on GOR in Infants From 0 to 12 Months. https://ClinicalTrials.gov/show/NCT02124863 Completed Vrije Universiteit Brussel 2015-01-31
NCT00747526 A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive https://ClinicalTrials.gov/show/NCT00747526 Completed Janssen Research & Development, LLC 2012-02-29
NCT00744419 Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants https://ClinicalTrials.gov/show/NCT00744419 Completed University of Louisville 2012-04-30
NCT00734747 Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00734747 Completed Medigus Ltd 2011-05-31
NCT00734097 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) https://ClinicalTrials.gov/show/NCT00734097 Completed AstraZeneca 2008-10-31
NCT00729339 Role of Mosapride in Patients With Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00729339 Completed Lotung Poh-Ai Hospital 2009-04-30
NCT00728481 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis https://ClinicalTrials.gov/show/NCT00728481 Completed Mayo Clinic 2010-12-31
NCT00693225 Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study https://ClinicalTrials.gov/show/NCT00693225 Completed Mayo Clinic 2010-12-31
NCT00660660 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US https://ClinicalTrials.gov/show/NCT00660660 Completed AstraZeneca 2008-07-31
NCT00658775 Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00658775 Completed Eisai Inc. 2009-09-30
NCT00658632 Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00658632 Completed Eisai Inc. 2009-04-30
NCT00658528 Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00658528 Completed Eisai Inc. 2009-09-30
NCT00634114 Reflux Esophagitis Phase III Study (Maintenance Treatment) https://ClinicalTrials.gov/show/NCT00634114 Completed AstraZeneca NA
NCT00633932 Reflux Esophagitis Phase III Study (Initial Treatment) https://ClinicalTrials.gov/show/NCT00633932 Completed AstraZeneca NA
NCT00628342 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00628342 Completed AstraZeneca 2003-08-31
NCT00627016 A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn https://ClinicalTrials.gov/show/NCT00627016 Completed Takeda 2009-03-31
NCT00626535 A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD) https://ClinicalTrials.gov/show/NCT00626535 Completed AstraZeneca 2004-02-29
NCT00626262 Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv https://ClinicalTrials.gov/show/NCT00626262 Completed AstraZeneca 2002-10-31
NCT00625495 Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00625495 Completed AstraZeneca 2002-11-30
NCT00618150 Patient Education in Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00618150 Completed Norwegian University of Science and Technology 1999-12-31
NCT00464308 A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg https://ClinicalTrials.gov/show/NCT00464308 Completed Janssen-Cilag Pty Ltd 2008-05-31
NCT00414856 Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux https://ClinicalTrials.gov/show/NCT00414856 Completed Novartis NA
NCT00394472 Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients https://ClinicalTrials.gov/show/NCT00394472 Completed AstraZeneca 2007-06-30
NCT00820079 ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD) https://ClinicalTrials.gov/show/NCT00820079 Completed Addex Pharma S.A. 2009-10-31
NCT00373334 Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00373334 Completed Braintree Laboratories 2008-02-29
NCT00365300 Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00365300 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2007-11-30
NCT00346905 Endoscopic Implantation of Enteryx for the Treatment of GERD https://ClinicalTrials.gov/show/NCT00346905 Completed Beth Israel Deaconess Medical Center 2008-02-29
NCT00326027 Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004) https://ClinicalTrials.gov/show/NCT00326027 Completed Nycomed 2007-07-31
NCT00325676 Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342) https://ClinicalTrials.gov/show/NCT00325676 Completed Takeda NA
NCT00324974 The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux https://ClinicalTrials.gov/show/NCT00324974 Completed Takeda 2007-05-31
NCT00321984 Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00321984 Completed Takeda 2006-12-31
NCT00321737 Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis https://ClinicalTrials.gov/show/NCT00321737 Completed Takeda 2007-05-31
NCT00312806 Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341) https://ClinicalTrials.gov/show/NCT00312806 Completed Takeda 2007-03-31
NCT00307944 Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea https://ClinicalTrials.gov/show/NCT00307944 Completed University of Cincinnati NA
NCT00300755 Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00300755 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2008-04-30
NCT00261339 Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506) https://ClinicalTrials.gov/show/NCT00261339 Completed Takeda NA
NCT00255164 Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis https://ClinicalTrials.gov/show/NCT00255164 Completed Takeda 2006-11-30
NCT00255151 Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis https://ClinicalTrials.gov/show/NCT00255151 Completed Takeda 2006-11-30
NCT00251927 Esomeprazole (NEXIUM) vs. Surgery https://ClinicalTrials.gov/show/NCT00251927 Completed AstraZeneca 2009-04-30
NCT00251758 Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn https://ClinicalTrials.gov/show/NCT00251758 Completed Takeda 2006-05-31
NCT00251745 Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn https://ClinicalTrials.gov/show/NCT00251745 Completed Takeda 2006-05-31
NCT00251719 Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis https://ClinicalTrials.gov/show/NCT00251719 Completed Takeda 2007-01-31
NCT00251693 Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis https://ClinicalTrials.gov/show/NCT00251693 Completed Takeda 2007-01-31
NCT00246909 Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340) https://ClinicalTrials.gov/show/NCT00246909 Completed Takeda 2006-11-30
NCT00237367 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn https://ClinicalTrials.gov/show/NCT00237367 Completed PriCara, Unit of Ortho-McNeil, Inc. NA
NCT00235677 Treatment Of Gastroesophageal Reflux Disease By Endoscopic Fundoplication, A Placebo-Controlled Study https://ClinicalTrials.gov/show/NCT00235677 Completed UMC Utrecht NA
NCT00229424 Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine - https://ClinicalTrials.gov/show/NCT00229424 Completed Taiho Pharmaceutical Co., Ltd. 2006-10-31
NCT00220818 A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease. https://ClinicalTrials.gov/show/NCT00220818 Completed Takeda 2005-07-31
NCT00217347 Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy https://ClinicalTrials.gov/show/NCT00217347 Completed Nantes University Hospital NA
NCT00216489 A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00216489 Completed Janssen Cilag Pharmaceutica S.A.C.I., Greece NA
NCT00206180 NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis https://ClinicalTrials.gov/show/NCT00206180 Completed AstraZeneca NA
NCT00200642 Evaluation of the Efficiency of Radiofrequency in the Treatment of Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00200642 Completed Nantes University Hospital NA
NCT00194376 Evaluation of Gastroesophageal Reflux in Patients on Continuous Positive Airway Pressure Ventilation for Obstructive Sleep Apnea https://ClinicalTrials.gov/show/NCT00194376 Completed University of Pennsylvania 2006-09-30
NCT00174928 A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00174928 Completed Takeda 2005-08-31
NCT00171483 Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). https://ClinicalTrials.gov/show/NCT00171483 Completed Novartis NA
NCT00171418 Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). https://ClinicalTrials.gov/show/NCT00171418 Completed Novartis NA
NCT00165672 A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00165672 Completed Eisai Inc. 2005-10-31
NCT00165646 A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00165646 Completed Eisai Inc. 2005-10-31
NCT00164840 Symptomatic Gastroesophageal Reflux Disease: Double Blind Randomized Controlled Study of On-demand Therapy Versus Maintenance Therapy https://ClinicalTrials.gov/show/NCT00164840 Completed Chinese University of Hong Kong 2008-11-30
NCT00163306 Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339) https://ClinicalTrials.gov/show/NCT00163306 Completed Takeda NA
NCT00141960 Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00141960 Completed Astellas Pharma Inc NA
NCT00132496 Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole https://ClinicalTrials.gov/show/NCT00132496 Completed Eisai Inc. 2006-05-31
NCT00131248 Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants https://ClinicalTrials.gov/show/NCT00131248 Completed The University of Texas Health Science Center, Houston 2008-03-31
NCT00057174 Economic Impact of Guidelines for Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00057174 Completed VA Office of Research and Development NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03824548 Outcomes for Patients With Gastro-Esophageal Reflux Disease https://ClinicalTrials.gov/show/NCT03824548 Recruiting Tianjin Happy Life Technology Co., Ltd. 2019-05-01
NCT03214952 Drug Use Surveillance of Vonoprazan for “Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis” https://ClinicalTrials.gov/show/NCT03214952 Completed Takeda 2018-10-31
NCT03053609 Gastroesophageal Reflux and Cardiorespiratory Problems https://ClinicalTrials.gov/show/NCT03053609 Completed University of Turin, Italy 2016-12-31
NCT03005080 Pharmacogenetic Testing in Children With Persistent Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT03005080 Completed Mayo Clinic 2017-12-31
NCT02837627 Effect of Tube Feeding on Gastroesophageal Reflux in Preterm Infants https://ClinicalTrials.gov/show/NCT02837627 Enrolling by invitation Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi 2021-04-30
NCT02797756 Impact of Gastroesophageal Reflux and Aspiration on Airway Inflammation and Microbiome in Children With Chronic Cough https://ClinicalTrials.gov/show/NCT02797756 Completed NYU Langone Health 2018-12-12
NCT02506634 The Primary Symptoms of GERD(Gastroesophageal Reflux Disease) in Chinese Outpatients in Gastroenterology Department https://ClinicalTrials.gov/show/NCT02506634 Completed First Affiliated Hospital, Sun Yat-Sen University 2019-01-31
NCT02477475 Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes https://ClinicalTrials.gov/show/NCT02477475 Completed AstraZeneca 2017-02-20
NCT02437682 Translation and Validation of the PASS Test for GERD Patients With Partial Response to PPI: PASS-HK https://ClinicalTrials.gov/show/NCT02437682 Recruiting Chinese University of Hong Kong 2019-12-31
NCT02167984 Esophageal Bolus Transit in Newborns With Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT02167984 Completed University of Turin, Italy 2013-03-31
NCT02023216 Effects of Non-Nutritive Sucking on Gastroesophageal Reflux and Related Apneas in Symptomatic Preterm Infants https://ClinicalTrials.gov/show/NCT02023216 Completed Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi 2015-08-31
NCT01990339 Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms https://ClinicalTrials.gov/show/NCT01990339 Completed Takeda 2010-12-31
NCT01601379 Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease. https://ClinicalTrials.gov/show/NCT01601379 Completed Janssen-Cilag International NV 2011-06-30
NCT01562639 Nexium Capsules RE Maintenance Specific Clinical Experience Investigation https://ClinicalTrials.gov/show/NCT01562639 Completed AstraZeneca 2014-07-31
NCT01536457 Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Analysis Only https://ClinicalTrials.gov/show/NCT01536457 Completed Children’s Center for Digestive Health Care 2012-09-30
NCT01536080 Analysis of GERD Symptoms Using Gastroesophageal Reflux Impact Score Questionnaire for Quality of Life https://ClinicalTrials.gov/show/NCT01536080 Completed Seoul National University Bundang Hospital NA
NCT01434485 Nexium Capsules Clinical Experience Investigation https://ClinicalTrials.gov/show/NCT01434485 Completed AstraZeneca 2014-03-31
NCT01432392 Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT01432392 Completed AstraZeneca 2012-04-30
NCT01321567 Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis https://ClinicalTrials.gov/show/NCT01321567 Completed Eisai Inc. 2013-03-01
NCT01921686 Morphological Markers of Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT01921686 Active, not recruiting Baylor College of Medicine 2014-09-30
NCT04248296 Evaluate the Intestinal Microbiome in Patients With Erosive Gastroesophageal Reflux Disease and in Asymptomatic Healthy Controls https://ClinicalTrials.gov/show/NCT04248296 Completed University of Sao Paulo General Hospital 2019-02-20
NCT04034017 Gastroesophageal Reflux Disease Among College Students https://ClinicalTrials.gov/show/NCT04034017 Completed King Khalid University 2019-06-01
NCT03848494 True Short Esophagus in Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT03848494 Completed University of Bologna 2017-12-31
NCT03735862 Complications, Outcomes and Revisions Following Hiatal Hernia Repair With MIROMESH https://ClinicalTrials.gov/show/NCT03735862 Completed Miromatrix Medical Inc. 2018-06-01
NCT03669874 Endoscopic Fundoplication With MUSE System https://ClinicalTrials.gov/show/NCT03669874 Recruiting IRCCS San Raffaele 2021-09-16
NCT01215305 A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Disease(GERD) in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece https://ClinicalTrials.gov/show/NCT01215305 Completed AstraZeneca 2011-03-31
NCT01204931 Can We Predict Who Has Gastroesophageal Reflux Disease (GERD)? https://ClinicalTrials.gov/show/NCT01204931 Completed Vanderbilt University 2013-07-31
NCT01200550 The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients https://ClinicalTrials.gov/show/NCT01200550 Completed AstraZeneca 2011-09-30
NCT01194323 Biology in Patients With Reflux Esophagitis https://ClinicalTrials.gov/show/NCT01194323 Completed Vanderbilt University Medical Center 2012-12-31
NCT01167543 Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease https://ClinicalTrials.gov/show/NCT01167543 Completed University of California, San Francisco NA
NCT01020890 Prevalence of Gastroesophageal Reflux Disease in Primary Care Patients With Upper Gastrointestinal Symptoms https://ClinicalTrials.gov/show/NCT01020890 Completed AstraZeneca 2010-04-30
NCT01018160 Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea https://ClinicalTrials.gov/show/NCT01018160 Completed Janssen Korea, Ltd., Korea 2009-02-28
NCT00963144 Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study https://ClinicalTrials.gov/show/NCT00963144 Completed AstraZeneca 2009-11-30
NCT00951093 Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass https://ClinicalTrials.gov/show/NCT00951093 Completed Clinica Gastrobese 2012-12-31
NCT00920400 Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract https://ClinicalTrials.gov/show/NCT00920400 Completed University Hospital, Basel, Switzerland 2009-09-30
NCT00914342 Prevalence and Impact in Work Productivity of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients With Upper Gastrointestinal (GI) Symptoms Using GerdQ https://ClinicalTrials.gov/show/NCT00914342 Completed AstraZeneca NA
NCT00901004 The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire https://ClinicalTrials.gov/show/NCT00901004 Completed AstraZeneca NA
NCT00886197 Diagnostic Efficacy of Narrow Band Imaging in Patients With Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00886197 Completed National Taiwan University Hospital 2009-04-30
NCT00859287 Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis https://ClinicalTrials.gov/show/NCT00859287 Completed AstraZeneca NA
NCT03214081 Special Drug Use Surveillance of Vonoprazan for “Maintenance Therapy of Reflux Esophagitis: Long-term Use” https://ClinicalTrials.gov/show/NCT03214081 Completed Takeda 2018-08-31
NCT00768443 Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD) https://ClinicalTrials.gov/show/NCT00768443 Completed AstraZeneca NA
NCT00768196 Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients https://ClinicalTrials.gov/show/NCT00768196 Completed AstraZeneca NA
NCT00730106 Endoscopic Findings in Patients With Typical Gastroesophageal Reflux Disease (GERD) Symptoms https://ClinicalTrials.gov/show/NCT00730106 Completed Lotung Poh-Ai Hospital 2009-07-31
NCT00698178 Waist Circumference Versus Body Mass Index to Predict Severity of Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00698178 Completed Lotung Poh-Ai Hospital 2009-07-31
NCT00681837 Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France https://ClinicalTrials.gov/show/NCT00681837 Completed AstraZeneca NA
NCT00586963 Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis https://ClinicalTrials.gov/show/NCT00586963 Completed Mayo Clinic 2008-10-31
NCT00574327 Progression of Gastroesophageal Reflux Disease and Barrett’s Esophagus and the Creation of a Barrett’s Registry https://ClinicalTrials.gov/show/NCT00574327 Recruiting Midwest Biomedical Research Foundation 2023-10-31
NCT00561730 Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD) https://ClinicalTrials.gov/show/NCT00561730 Completed Nycomed NA
NCT00481949 Assessment of Gastro-esophageal Reflux Using Endo-Flip vs Bravo https://ClinicalTrials.gov/show/NCT00481949 Completed Guy’s and St Thomas’ NHS Foundation Trust 2011-05-31
NCT00462137 The Influence of Hypnotic Medications on Sleep Arousal and Its Effect on Gastroesophageal Reflux https://ClinicalTrials.gov/show/NCT00462137 Completed Thomas Jefferson University 2008-03-31
NCT00461604 High Dosage Esomeprazole and Baclofen for Therapy of Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00461604 Completed Technische Universität München 2008-05-31
NCT00260572 Outcomes After Medical and Surgical Treatment of Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT00260572 Active, not recruiting University of Pittsburgh 2050-12-31
NCT00165022 Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population https://ClinicalTrials.gov/show/NCT00165022 Completed Chinese University of Hong Kong NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT01954667 Anthropometric Measures and Severity of Gastroesophageal Reflux Disease https://ClinicalTrials.gov/show/NCT01954667 Completed Ain Shams University 2013-08-31
NCT03661151 Comparison of Treatment Outcome and Cost-effectiveness for GERD https://ClinicalTrials.gov/show/NCT03661151 Recruiting Korea University Anam Hospital 2020-10-25
NCT03616119 Gastroesophageal Reflux Disease in Azerbaijan https://ClinicalTrials.gov/show/NCT03616119 Active, not recruiting Azerbaijan Gastroenterology and Hepatology Association 2019-08-01
NCT03524781 Treatment of Newly Diagnosed Gastroesophageal Reflux Disease in a National Population-based Cohort https://ClinicalTrials.gov/show/NCT03524781 Active, not recruiting University of Southern Denmark 2019-01-01